Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Retrospective cohort study evaluating impact of osteolytic lesions on outcomes in pts w/ LPL/Waldenstrom macroglobulinemia finds they do not affect diagnosis-to-treatment interval, response to 1st-line therapy, PFS or OS.”
Title: Impact of baseline osseous involvement on outcomes in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia
Authors: John Sharp, Subodh Bhatta, Noah Takacs, Kathleen Tong, Youssef Youssef, David A. Bond, Yazeed Sawalha, Audrey Sigmund, Lapo Alinari, Robert Baiocchi, Kami Maddocks, Beth Christian, Timothy J. Voorhees, Narendranath Epperla
You can read the Full Article in Blood Neoplasia.
You can find other articles featuring Robert Orlowski on OncoDaily.
